VOR:NASDAQVor Biopharma Inc. Analysis
Data as of 2026-08-11 - not real-time
$23.04
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Vor Biopharma Inc. is priced at $23.04 and its moving averages line up in bullish order, the shorter sitting above the longer. Over a rolling month the price has gained 23.9%. RSI sits at 66.2, which reads as approaching overbought, and MACD momentum is bullish. Price has been bracketed by support at $16.67 and resistance at $24.34.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 64.4% above the current price.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 74.8%, a beta of 1.36 and a maximum drawdown of 85.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 1/10 conviction on the long call.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 64.4% above the current price.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 74.8%, a beta of 1.36 and a maximum drawdown of 85.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 1/10 conviction on the long call.
Top Market Events
In late June 2026, Vor Biopharma Inc. was added to a broad suite of FTSE Russell indices, including the Russell 2000,...BOSTON, July 07, 2026 GLOBE NEWSWIRE -- Vor Bio Nasdaq: VOR , a clinical-stage biotechnology company transforming the...BOSTON, July 02, 2026 GLOBE NEWSWIRE -- Vor Bio Nasdaq: VOR , a clinical-stage biotechnology company transforming the...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 15.31
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 15.31
- Analyst targets imply +64.4% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +64.4% versus the current price
- Negative free cash flow
- 30-day volatility of 74.8%
Key Metrics & Analysis
Financial Health
P/E Ratio-6.2
ROA-69.76%
P/B Ratio-8.3
Op. Cash Flow$-149892992
Free Cash Flow$-188829120
Industry P/E30.1
Technical Analysis
TrendBullish
RSI66.2
Support$16.67
Resistance$24.34
MA 20$20.52
MA 50$17.85
MA 200$15.31
MACDBullish
VolumeDecreasing
Fear & Greed Index93.63
Valuation
Target Price$37.88
Upside/Downside64.39%
GradeFair
TypeBlend
Risk Assessment
Beta1.36
Volatility74.85%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.